Status:
COMPLETED
Safety, Tolerability, Pharmacokinetics, and Food Effect of BLU-782 in Healthy Adults
Lead Sponsor:
Blueprint Medicines Corporation
Conditions:
Healthy Volunteers
Eligibility:
All Genders
19-65 years
Phase:
PHASE1
Brief Summary
The main objectives of this study are to assess the safety, tolerability, pharmacokinetics (PK), and food effect of BLU-782 in healthy adult subjects.
Eligibility Criteria
Inclusion
- Medically healthy
- Non-smoker
- Body mass index (BMI) ≥ 18 and ≤ 32 kg/m2
- No clinically significant cardiac history
- No current electrocardiogram (ECG) abnormality
- Female must not be of childbearing potential
Exclusion
- History of or current mental or legal incapacitation or major emotional problems
- History or current clinically significant medical/psychiatric condition/disease
- History of any illness that, in the opinion of the Investigator, might impact the results of the study or pose an additional risk to the participant
- History or current alcoholism/drug abuse
- History or current allergy to the study drug or a similar drug
Key Trial Info
Start Date :
February 12 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 11 2019
Estimated Enrollment :
108 Patients enrolled
Trial Details
Trial ID
NCT03858075
Start Date
February 12 2019
End Date
September 11 2019
Last Update
November 8 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Undisclosed
Lincoln, Nebraska, United States, 68502